GeoVax Labs Inc.

254 articles with GeoVax Labs Inc.

• GeoVax and Virometix to Collaborate on Immunotherapy Program for HPV Infections and Related Cancers

  11/13/2018

  GeoVax Continues Expansion of International Collaborative Efforts for its Unique MVA-VLP Vaccine Technology

• GeoVax Reports 2018 Third Quarter Financial Results and Provides Corporate Update

  11/8/2018

  GeoVax Labs, Inc. announced its financial results for the quarter ended September 30, 2018, and provided an update on its research and development programs.

• GeoVax Presenting at Upcoming November 2018 Scientific Conferences

  11/7/2018

  Plug & Play Platform Continues to be Recognized for Distinct Benefits

• New Study Suggests Zika Virus Eradication in the Americas May Become Impossible, Making the Need for a Vaccine Even More Critical

  11/5/2018

  GeoVax Comments on New Study Conducted in Brazil

• GeoVax Announces Further Positive Results of its HIV Preventive Vaccine Program at International HIV Research Conference

  10/24/2018

  Booster Vaccination After ~7 Years Resulted in 600-fold Increase in Antibody Response

• GeoVax Announces Publication of HIV Vaccines Review

  10/22/2018

  Comprehensive Review Published in the Peer-Reviewed Journal, Clinical Pharmacology and Therapeutics

• GeoVax Observes National Latinx AIDS Awareness Day

  10/15/2018

  GeoVax Labs, Inc. today is observing National Latinx AIDS Awareness Day, a time to focus on the continuing and disproportionate impact of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) on Hispanics/Latinos in the United States. 

• GeoVax Observes National Gay Men'sHIV/AIDS Awareness Day

  9/27/2018

  GeoVax Labs, Inc. today is observing National Gay Men’s HIV/AIDS Awareness Day

• GeoVax Awarded $2.4 Million from U.S. Department of Defense to Advance Lassa Fever Vaccine

  9/26/2018

  GeoVax Labs, Inc. announced today that the U.S. Department of Defense (DoD) has awarded the Company a $2,442,307 cooperative agreement in supportof its novel Lassa Fever (LF) vaccine development program.

• GeoVax Comments on Age-Associated HIV Infection Trends in the U.S.

  9/24/2018

  GeoVax Labs Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on recent age-associated HIV infection trends observed in the United States. 

• GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation

  9/19/2018

  Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis

• GeoVax to Report Vaccine Development Progress at the 12th Vaccine Congress in Budapest

  9/13/2018

  GeoVax Labs, Inc. announced today that its Chief Scientific Officer, Dr. Farshad Guirakhoo, will deliver a talk during the 12th Vaccine Congress, organized by Elsevier and Vaccine journal, being held September 16-19, 2018 in Budapest, Hungary. 

• GeoVax Strengthens Scientific Staff and Expertise

  8/29/2018

  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced the strengthening of its scientific team through the addition of two PhD-level scientists.  

• GeoVax Comments on Recent Paper Addressing Safety Concerns Over Ebola Vaccines Under Development

  8/23/2018

  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a paper published by Iampietro et al, from the Department of Pathology, University of Texas Medical Branch at Galveston, Texas, in The Journal of Infectious Diseases, concerning new findings on how the Ebola virus (EBOV) disables the host immune system and spreads infection. 

• GeoVax and PharmaJet to Collaborate On Development of Needle-Free Vaccine for Zika Virus

  8/21/2018

  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with  PharmaJet, Inc., on the evaluation of PharmaJet’s needle-free injection system for administration of GeoVax’s Zika vaccine.

• GeoVax Announces Appointment of David Dodd as Chairman, President and Chief Executive Officer

  8/14/2018

  GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement.

• GeoVax and Vaxeal to Collaborate on Cancer Immunotherapy Program

  1/3/2018

  GeoVax's immuno-oncology program is based on its Modified Vaccinia Ankara Virus-Like Particle platform

• GeoVax HIV Clinical Trials Update

  11/15/2017

  GeoVax Labs today announced that the HIV Vaccine Trials Network has closed enrollment for the phase 1 human clinical trial evaluating late boosts of GeoVax's preventive vaccine (GOVX-B11) for clade B HIV.

• GeoVax to Present at the Third International Conference on Vaccines Research and Development

  11/13/2017

  Dr. Guirakhoo will discuss GeoVax's vaccine platform which utilizes its recombinant Modified Vaccinia Ankara (MVA) vector to express foreign antigens on virus-like particles (VLPs) in the person being vaccinated.

• GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates

  11/10/2017

  GeoVax reported a net loss of $588,787 ($0.01 per share) for the three months ended September 30, 2017, compared to $464,200 ($0.01 per share) for the same period in 2016.